SBIR-STTR Award

Immuno-Cometchip for Human Skin Basal Cell Genotoxicity Testing
Award last edited on: 5/14/2020

Sponsored Program
STTR
Awarding Agency
NIH : NIEHS
Total Award Amount
$1,654,255
Award Phase
2
Solicitation Topic Code
113
Principal Investigator
Peter Sykora

Company Information

Trevigen Inc

8405 Helgerman Court
Gaithersburg, MD 20877
   (301) 216-2800
   info@trevigen.com
   www.trevigen.com

Research Institution

Georgetown University

Phase I

Contract Number: 1R41ES026908-01
Start Date: 6/1/2016    Completed: 5/31/2017
Phase I year
2016
Phase I Amount
$152,999
The objective of this Phase 1 STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures (Epiderm) in response to commonly used chemical agents. The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis. Technical questions that will be addressed are 1) Can we modify our currently used Comet Chip assay to incorporate extracellular matrix proteins or antibodies? 2) Can we isolate individual basal keratinocytes from a 3D organotypic skin culture on the basis of their preferential adhesion to these matrix proteins, including collagen I and IV, or by using immobilized antibodies to integrin ?1? 3) Can we confirm their identity by quantum dot-coupled antibodies specific for ?2 or ?1 (collagen ligand), integrins? 4) Can we use the isolated, antibody-labeled epidermal basal cells to detect and quantify levels of DNA damage in response to known environmental genotoxic agents? 5) Can we use our Immuno-CometChip assay to screen large numbers of agents currently or proposed to be marketed? The impact of the proposed research will be to reduce animal model use for toxic agent screening, since human organotypic culture has been shown to be almost identical to human skin with respect to its cytokine profile in response to corrosive or irritating agents. The market for screening skin genotoxic agents is immense, since the current screening procedures cannot keep pace with the number of new agents currently being introduced. Aim 1 will be to develop a new method for the isolation of basal keratinocytes, and an immunostaining method for simultaneous visualization of specific antigens, including ?1 integrin and DNA damage. Aim 2 will be to validate the Immuno-CometChip assay using known DNA damaging agents, including H2O2. This adds three new parameters to the Comet assay. The first is obtaining 96 treatment groups of 240 single basal epidermal keratinocytes from an organotypic culture on a single chip, the second is verifying their identity with surface markers, and the third is the simultaneous reproducible assay for DNA damage.

Public Health Relevance Statement:


Public Health Relevance:
The Comet assay has appeal for many reasons. The assay is rapid, simple, sensitive, reliable, and fairly inexpensive. Its use for testing for skin toxicity hs been hampered by a number of factors, including background DNA damage incurred during the normal process of differentiation in organotypic skin models, which mimic human skin. We therefore propose to develop a Comet Chip assay, a high throughput, reproducible, and quantitative method to isolate basal keratinocytes and measure genotoxicity in response to commonly used chemical agents.

NIH Spending Category:
Bioengineering; Genetics; Nanotechnology; Prevention

Project Terms:
Address; Adhesions; Alkalies; Allergic; Animal Model; Antibodies; Antigens; Basal Cell; base; Binding; Biological Assay; Caliber; Cell Separation; Cells; Chemical Agents; Chemicals; chromatin immunoprecipitation; cold temperature; Collagen; Comet Assay; Corrosives; Coupled; Cryopreserved Cell; cytokine; Deposition; DNA Damage; Epidermis; Extracellular Matrix Proteins; fluorescence microscope; Gel; genotoxicity; Goals; Grant; Household; Human; Hydrogen Peroxide; Hypersensitivity skin testing; Imagery; Individual; Integrins; interest; keratinocyte; Label; Ligands; Light; Market Research; Marketing; Measures; Methods; Modeling; Monitor; Mutagenicity Tests; Mutagens; nanoparticle; New Agents; Peptide Hydrolases; Phase; Process; Proteins; Protocols documentation; public health relevance; Quantum Dots; rapid technique; Research; research and development; response; screening; Screening procedure; Sepharose; Skin; Small Business Technology Transfer Research; Staging; Stem cells; success; Surface; Techniques; Testing; Time; Toxic effect; Toxicity Tests; treatment group; Universities; Validation

Phase II

Contract Number: 2R42ES026908-02
Start Date: 6/1/2016    Completed: 4/30/2020
Phase II year
2018
(last award dollars: 2019)
Phase II Amount
$1,501,256

The objective of this STTR Phase II proposal is to utilize our proof-of concept results to develop and market an easy-to-use standardized platform to quantify genotoxicity specifically in basal cell skin keratinocytes from organotypic cultures (EpidermTM; MatTek) in response to commonly used chemical agents. The product is an automated high-throughput Immuno-CometChip assay that simultaneously isolates and verifies the basal layer origin of cells derived from an organotypic reconstructed human epidermis, and quantifies their level of DNA damage. The impact of the research will be to reduce animal model use for toxic agent screening, since human organotypic culture has been shown to be almost identical to human skin with respect to its response to corrosive, irritating, and allergic agents. The market for screening skin genotoxic agents is large, and current screening procedures cannot keep pace with new agents currently being introduced. Many of these agents are screened by companies, who will have an interest in a rapid method to determine at an early stage whether or not to proceed with research and development of lead compounds. We therefore propose the following Specific Aims: Specific Aim 1: To develop control cells to be included with each run of the Immuno-Comet Chip assay to ensure that our new method for the isolation of basal keratinocytes using a collagen I/agarose composite gel for our new CometChip platform (see below), will be successful for each run following an immunostaining method for simultaneous visualization of ?1 integrin along with DNA damage. Specific Aim 2: To develop computer software that only measures comets in integrin ?1-postive basal cells. Specific Aim 3: To determine activity of human epidermal cytochrome p450s (CYP) in the EpiDermTM organotypic model, in order to test if preincubation of procarcinogens and human S9 fractions is necessary. Specific Aim 4: To test 10 compounds each of carcinogens, procarcinogens and non-carcinogens from ?Toxicology in the 21st Century? (Tox21) in double-blinded fashion to determine if we can distinguish statistically significant difference between carcinogenic and non-carcinogenic compounds, and to determine if CYP enzymes are converting procarcinogens to carcinogens.